Wilson Sonsini Goodrich & Rosati advised FluoRok on patent matters related to the transaction. FluoRok, a deep-tech start-up focused on fluorochemical manufacturing, announced the completion of...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Ripple on the transaction. Ripple Therapeutics Corporation (Ripple) announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, a...
You must be a Standard 1 Year member to access this content.
Taft Stettinius & Hollister advised ONL Therapeutics on the transaction, and Wilson Sonsini Goodrich & Rosati advised the company on patent matters. ONL Therapeutics, Inc. announced...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery LLP acted as legal advisor to BPD on the transaction. BPD, the premier data-driven health system marketing services company in the United...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction. MapLight Therapeutics announced a $225 million Series C financing co-led by Novo Holdings, 5AM Ventures, Cowen...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery represented General Atlantic in the transaction. General Atlantic, a leading global growth equity investor, executed its $179 million growth investment into Gravie,...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery represented Vytalize Health in the transaction. Vytalize Health, a leading risk-bearing provider enablement platform, announced its acquisition of Independent Physician Association of...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented LENZ in the transaction. Biopharmaceutical company LENZ Therapeutics announced that it raised $83.5 million in an oversubscribed Series B financing....
You must be a Standard 1 Year member to access this content.
Skadden advised Centene Corporation in the deal. McDermott Will & Emery represented Prime Therapeutics LLC. Centene Corporation signed its definitive agreement to sell Magellan Rx to...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Excision BioTherapeutics on the deal. Excision BioTherapeutics, a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives,...
You must be a Standard 1 Year member to access this content.
